CNS Pharmaceuticals Appoints CFO, CTO and CBO with 15–30 Years Experience
CNS Pharmaceuticals has appointed Steven O'Loughlin as CFO, Eric Faulkner as CTO and Dylan Wenke as CBO on March 2, 2026 to support strategic transformation under new CEO Rami Levin. These executives bring over 15 to 30 years of biotech leadership to accelerate pipeline optimization, capital discipline and value creation.
1. Leadership Team Expansion
CNS Pharmaceuticals has appointed Steven O’Loughlin as Chief Financial Officer, Eric Faulkner as Chief Technology Officer and Dylan Wenke as Chief Business Officer, effective March 2, 2026. These appointments were made under new CEO Rami Levin to spearhead the company’s organizational evolution.
2. Strategic Transformation Framework
Following his appointment six weeks ago, CEO Rami Levin initiated a comprehensive pipeline and capital allocation review based on Patients First, Pipeline Enrichment and Disciplined Value Creation. The new team is expected to implement this framework to accelerate clinical programs and strategic transactions.
3. Executive Experience Profiles
O’Loughlin brings over 15 years of senior financial leadership and experience in equity financings and business development. Faulkner offers 30 years of scientific development and CMC leadership, while Wenke adds expertise in corporate development and high-value licensing transactions.
4. Future Outlook and Execution Milestones
The company anticipates additional updates as the strategic evaluation progresses, emphasizing disciplined growth, operational rigor and transparent communication with stakeholders. Management aims to generate meaningful data and value inflection points under this new leadership structure.